Pregnancy after breast cancer in BRCA1/2 mutation carriers
No Thumbnail Available
Date
2022-01-21
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. Methods: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. Main body of the abstract: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. Conclusion: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.
Description
Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)?Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme ?ERN-2016?Framework Partnership Agreement 2017?2021. Funding Information: This research is supported (not financially) by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN-2016—Framework Partnership Agreement 2017–2021. Publisher Copyright: © 2022, The Author(s).
Keywords
3.1 Basic medicine, 3.2 Clinical medicine, 1.1. Scientific article indexed in Web of Science and/or Scopus database, SDG 3 - Good Health and Well-being
Citation
Maksimenko, J, Irmejs, A & Gardovskis, J 2022, 'Pregnancy after breast cancer in BRCA1/2 mutation carriers', Hereditary Cancer in Clinical Practice, vol. 20, no. 1, 3, pp. 3. https://doi.org/10.1186/s13053-022-00209-1, https://doi.org/10.1186/s13053-022-00209-1